JUBLPHARMA.NS Cash Flow
Jubilant Pharmova Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 8 years on file
(FY2017-18 to FY2025-26)
· fetched 2026-08-23 23:33
| Line item | FY2017-18 | FY2019-20 | FY2020-21 standalone basis | FY2021-22 | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | N/A | N/A | N/A | ₹8.38 Bn | ₹6.61 Bn | ₹9.71 Bn | ₹10.72 Bn | ₹12.27 Bn | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | N/A | N/A | N/A | ₹-3.80 Bn | ₹-5.44 Bn | ₹-6.08 Bn | ₹4.88 Bn | ₹-12.60 Bn | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | N/A | N/A | N/A | ₹-0.33 Bn | ₹-1.57 Bn | ₹-4.33 Bn | ₹-14.53 Bn | ₹0.95 Bn | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | N/A | N/A | N/A | ₹0.57 Bn | ₹0.71 Bn | ₹0.12 Bn | ₹0.25 Bn | ₹1.17 Bn | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | N/A | N/A | N/A | ₹4.82 Bn | ₹0.30 Bn | ₹-0.57 Bn | ₹1.32 Bn | ₹1.79 Bn | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | N/A | N/A | N/A | ₹5.02 Bn | ₹9.84 Bn | ₹10.14 Bn | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from JUBLPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).